Morgan Stanley’s DICE Therapeutics, Inc. Common Stock DICE Stock Holding History

Morgan Stanley’s Portfolio DICE Stock Details DICE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-599,469	Closed	-$27.9M	–	7799
2023 Q2	$27.9M	Buy	599,469 +521,832	+672%	+$18M	﹤0.01%	2126
2023 Q1	$2.22M	Sell	77,637 -6,388	-8%	-$189K	﹤0.01%	4395
2022 Q4	$2.62M	Buy	84,025 +45,968	+121%	+$1.5M	﹤0.01%	4278
2022 Q3	$771K	Buy	38,057 +5,837	+18%	+$106K	﹤0.01%	5039
2022 Q2	$500K	Buy	32,220 +29,547	+1,105%	+$508K	﹤0.01%	5425
2022 Q1	$51K	Sell	2,673 -29,858	-92%	-$533K	﹤0.01%	6700
2021 Q4	$823K	Buy	+32,531	New	+$953K	﹤0.01%	5218

Morgan Stanley's DICE Position: Q3 2023 in Review

Morgan Stanley sold out of DICE Therapeutics, Inc. Common Stock (DICE) in Q3 2023, closing a stake of 599,469 shares — an estimated $27.9M sold.

Morgan Stanley first reported a position in DICE in Q4 2021 and held it in 7 quarters. The position peaked at $27.9M in Q2 2023. 0 funds tracked by Wall St. Rank hold DICE as of Q3 2023.

Morgan Stanley reported no remaining DICE Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
Morgan Stanley sold 599,469 DICE Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $27.9M.
Morgan Stanley first reported a position in DICE Therapeutics, Inc. Common Stock in Q4 2021 and held it in 7 quarters.
Morgan Stanley's DICE Therapeutics, Inc. Common Stock position peaked at $27.9M in Q2 2023.
0 funds tracked by Wall St. Rank held DICE Therapeutics, Inc. Common Stock as of Q3 2023.

Based on Morgan Stanley's 13F filing for Q3 2023, filed 15 Nov 2023.